MedPal AI plc (AIM: MPAL) has highlighted the potential expansion of the GLP-1 market after the US Food and Drug Administration approved Eli Lilly’s Mounjaro to reduce the risk of
MedPal highlights new UK oral weight-loss treatment
MedPal AI plc (AIM: MPAL) has highlighted the UK approval of Eli Lilly’s once-daily oral GLP-1 treatment, Foundayo, which has been authorised for weight loss and weight maintenance in eligible